ASCO 2024 | Results of the first SRI of MajesTEC-7: safety of tec-DR in transplant-ineligible newly diagnosed MM
Niels Van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, presents the results of the first safety run-in (SRI) of the Phase III MajesTEC-7 study (NCT05552222), which will investigate teclistamab in combination with daratumumab and lenalidomide (tec-DR) and talquetamab in combination with daratumumab and lenalidomide (tal-DR) in patients with newly diagnosed multiple myeloma (MM) who are transplant ineligible. In this first SRI, tec-DR demonstrated a manageable safety profile, a low discontinuation rate, and promising early efficacy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
